Results for the Quarter and Half Year ended September 30, 2026

Limited Date: November 03, 2026 Ref:- GHL/2026-27/EXCH/70 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Code: 543654 Symbol: MEDANTA Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Dear Sir(s), We would like to inform you that the Board of Directors of Global Health Limited (‘GHL/Company’) at its meeting held today i.e. Tuesday, November 03, 2026, has inter alia, approved the following: 1. Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter & Half Year ended September 30, 2026 (‘Financial Results’). The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as Exhibit-I. Further, we hereby declare and confirm that the Statutory Auditors of the Company, have issued the Limited Review Reports with an unmodified opinion on the Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2026 pursuant to the Listing Regulations. 2. The Project Budget of Rs. 997 Crores (including the cost of land) for construction of a 500 bedded hospital on the land parcel admeasuring 10560.36 sq. meters allotted by UP Housing & Development Board (UPAVP), at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh. The details as required under Regulation 30 are enclosed as Annexure-A (in continuation of our earlier intimation in this regard dated September 28, 2026). Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Limited The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges. The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 03:45 P.M. Thanking You, For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M.No. A17035 Encl: a/a Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Walker Chandiok &._Co LLP Walker Chandiok & Co LLP 21st Floor, DLF Square Jacaranda Marg, DLF Phase II, Gurugram -122 002 Haryana, India T +91 124 462 8099 F +91 124 462 8001 Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Global Health Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement’) of Global Health Limited (‘the Company’) which includes GHL Employee Welfare Trust (‘the Trust’) for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (‘Listing Regulations’). 2. The Statement, which is the responsibility of the Company’s management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (‘the Act’), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Chartered Accountants Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, and has its registered office at L-41, Connaught New Delhi, Noida and Pune Circus, Outer Circle, New Delhi, 110001, India Walker Chandiok &_Co LLP Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont’d) 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 Tarun Gupta Partner Membership No. 507892 UDIN: 26507892KTIZMA2964 Place: Gurugram Date: 03 November 2026 Chartered Accountants Glohel Health Limited R,iistered Off",a,: Medaab Medidiaic, E-111, Defence Colony, New Delhi -110024, India Corporate Of'lke: Medaata-lloe Medicity, Sector-311, Gurgaon, Haryana -122001, India CIN:U51 I0DU004PLCl2S319 Tel: +91 124 483 4060; E-mail: compliaac:e@~org; Website: https://www.medanta.org Statement of standalone umadited fi---i reatts for the quarter and six months ended 30 Septtmber 2026 (' in millions, unl.ss otherwise stated) Qaa.-ended Six months ended Year ended S No. Particulan 30 Septm,ber 2026 JOJ-2026 JO September 2025 30 September 2026 30 September 2025 31 March 2026 Umadited Uandited Umadited Unaudited Unaudited Audited Income I Revenue from operations 12,080.94 10,787.23 9,264.28 22,868.17 18.085.84 37,093.78 II Other income 258.89 240.60 228.00 499.49 459.39 1,064.08 T-lincome 12,33'-83 11,1127.83 9,492.28 23,367.66 111,545.23 311,157.86 Ill Expemes Cost of materials conswned 2,446.15 2,261.59 2,032.16 4,707.74 3,953.79 7,858.56 Purchases of stock-in-trade 0.08 (0.44) 0.08 25.15 19.43 Changes in inventories of stock-in-trade 0.52 40.13 46.11 Employee benefits expense 3.013 97 2,854.73 2,483.33 5.868.70 4,812.78 9,892.59 Finance costs 170.65 158.90 88.83 329.55 145.41 410.85 Depreciation and amortisation expense 561.51 546.04 374.28 1,107.55 708.36 1.709.07 Retainers and consultants fee 1,750.81 1,659.19 1,282.33 3,410.00 2,375 14 5.445.32 Other expenses 1,965.90 1,716.28 1,540.65 3,682.18 3 007.31 6,283.16 Total expenses 9,909.07 ,.196. 73 7,801.66 19,105.80 15,068.07 •3 1,665.09 IV Profit befon exceptional itemo and tax 2,-00.76 1,831.10 1,690.62 4,261.86 3,477.16 6,492.77 Exceptional items (refer note 6) ( [Showing first 8,000 characters — download PDF for full document]